Prof. Dr. NURİYE ÖZDEMİR

1. The effect of switching from ribociclib to palbociclib due to toxicity in hormone receptor-positive, HER2-negative metastatic breast cancer: a real-world, multicenter, retrospective study

Oruç A., Deliktaş Onur İ., Uyar G. C., Şahin T. K., Tünbekici S., ARSLAN KAPUCİ A., et al.

Scientific Reports , cilt.16, sa.1, 2026 (SCI-Expanded, Scopus)

2. Real-world effectiveness of total neoadjuvant therapy in locally advanced rectal cancer: a multicenter retrospective study

SÜTCÜOĞLU O., AKDOĞAN O., Onur İ. D., Çiftçi A., Alkan A., Majidova N., et al.

Discover Oncology , cilt.17, sa.1, 2026 (SCI-Expanded, Scopus)

3. Key Methodological Considerations in the Interpretation of the CONKO-007 Trial

AKDOĞAN O., ÖZET A., YAZICI O., ÖZDEMİR N., SÜTCÜOĞLU O.

Journal of Clinical Oncology , 2026 (SCI-Expanded, Scopus)

4. Immunomodulatory Effect of First-Line Cisplatin Versus Carboplatin in Response to Second-Line Nivolumab Therapy in Metastatic Non-Small Cell Lung Cancer

AKDOĞAN O., BÖLEK H., Baskurt K., Akay Hacan B., SÜTCÜOĞLU O., Bir Yucel K., et al.

CANCER INVESTIGATION , cilt.44, sa.3, ss.248-256, 2026 (SCI-Expanded, Scopus)

5. Clinicopathological Characteristics of Metastatic Colorectal Cancer Patients with Prolonged Survival

EROĞLU İ., SÜTCÜOĞLU O., SAVAŞ G., GÜRLER F., COŞKUN U., ÜNER A., et al.

Journal of oncological sciences , cilt.11, ss.244-252, 2025 (Scopus, TRDizin)

6. Real-World Experience with Non-Metastatic Male Breast Cancer: A 222-Patient Multicenter Study from the Turkish Oncology Group (TOG).

Arslan Ü. Y., Aslan F., Ayhan M., Akdeniz N., Tahtacı G., Çınkır H. Y., et al.

Cancers , cilt.17, sa.24, 2025 (SCI-Expanded, Scopus)

7. Evaluation of 30-day mortality rate following intravenous systemic anticancer therapy: a retrospective analysis

ÇETİN T. E., SÜTCÜOĞLU O., AKDOĞAN O., SAVAŞ G., Günel N., ÜNER A., et al.

BMC Cancer , cilt.25, sa.1, 2025 (SCI-Expanded, Scopus)

8. Evaluation of Volumetric Magnetic Resonance Imaging in Determining the Indication for Total Neoadjuvant Therapy in Rectal Cancer

SÜTCÜOĞLU O., Leyla S., BİR YÜCEL K., ÖZET A., İNAN M. A., YAZICI O., et al.

JOURNAL OF GASTROINTESTINAL CANCER , cilt.56, sa.1, 2025 (ESCI, Scopus)

9. Splenic index score as a predictor of outcomes in metastatic non small cell lung cancer patients treated with immune checkpoint inhibitors

ASLAN V., KARABÖRK KILIÇ A. C., Rustamova Cennet N., YÜCEL T. A., kurt inci B., GÜRLER F., et al.

Scientific Reports , cilt.15, sa.1, 2025 (SCI-Expanded, Scopus)

10. Efficacy and safety of neoadjuvant FLOT treatment for resectable gastric/gastroesophageal junction adenocarcinoma in Turkish and German patients; a real-world data

Eroğlu İ., Möhring C., Sadeghlar F., Mańczak A., Yazıcı O., Özet A., et al.

BMC CANCER , cilt.25, sa.1, 2025 (SCI-Expanded, Scopus)

11. Induction chemotherapy followed by definitive chemoradiation in patients with inoperable esophageal squamous cell carcinoma: a multicenter retrospective study

Sahin T. K., Eroglu İ., Dilli I., Sutcuoglu O., Chalabiyev E., Guven D. C., et al.

DISCOVER ONCOLOGY , cilt.16, sa.1, 2025 (SCI-Expanded, Scopus)

12. The Responsiveness of Breast Cancer Cells to Varied Levels of Vitamin B12, Cisplatin, and G-CSF

ASLAN V., Usta D. D., YAR SAĞLAM A. S., ÖZET A., SÜTCÜOĞLU O., DİKMEN K., et al.

International Journal of Molecular Sciences , cilt.26, sa.18, 2025 (SCI-Expanded, Scopus)

13. Evaluating the role of step counts in predicting readmission and mortality (STEP-CANCER)

SÜTCÜOĞLU O., AKDOĞAN O., Uyar G. C., ÖZET A., Baskurt K., Ozdemir N., et al.

ANNALS OF ONCOLOGY , cilt.36, 2025 (SCI-Expanded, Scopus)

14. Biological age predicts survival outcomes in patients treated with immune checkpoint inhibitor monotherapy: A retrospective analysis

Tuzcu T. U., SÜTCÜOĞLU O., AKDOĞAN O., YAZICI O., ÖZDEMİR N., ÖZET A.

ANNALS OF ONCOLOGY , cilt.36, 2025 (SCI-Expanded, Scopus)

15. Predictive Value of the Royal Marsden Hospital Score in Second-line Immunotherapy for Metastatic NSCLC

Aslan V., Rustamova Cennet N., ÖZET A., ÖZDEMİR N., YAZICI O.

Journal of Oncological Science , cilt.11, sa.2, ss.126-133, 2025 (Scopus, TRDizin)

16. Neurotoxicity-related treatment discontinuations in PRODIGE 51-FFCD-GASTFOX

UgurTuzcu T., SÜTCÜOĞLU O., AKDOĞAN O., YAZICI O., ÖZDEMİR N.

LANCET ONCOLOGY , cilt.26, sa.8, 2025 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

17. Prostat kanserinde Lutetium-177-PSMA tedavisi: tek merkezli gerçek yaşam deneyimi

Akdoğan O., Sütcüoğlu O., Gülbahar Ateş S., Gürler F., Aydos U., Savaş G., et al.

Turkish Journal of Clinics and Laboratory , cilt.16, sa.3, ss.459-464, 2025 (TRDizin)

18. Evaluation of treatment protocols based on the ESMO-magnitude of clinical benefit scale for gastrointestinal system cancers and their relationship with reimbursement policies in Turkey

AKDOĞAN O., SÜTCÜOĞLU O., Yucel K. B., YAZICI O., ÖZET A., ÖZDEMİR N.

JOURNAL OF CANCER POLICY , cilt.44, 2025 (ESCI, Scopus) Sürdürülebilir Kalkınma

19. Comparison of clinicopathological features in early-onset breast cancer patients with and without pathogenic genetic mutation.

Kocoglu S. S., Eroglu I., Yildirim I., Ergun M. A., Savas G., Yazici O., et al.

JOURNAL OF CLINICAL ONCOLOGY , cilt.43, sa.16_SUPPL, 2025 (SCI-Expanded, Scopus)

20. Effect of a ChatGPT-based digital counseling intervention on anxiety and depression in patients with cancer: A prospective, randomized trial

AKDOĞAN O., Uyar G. C., Yesilbas E., Baskurt K., MALKOÇ N. A., ÖZDEMİR N., et al.

EUROPEAN JOURNAL OF CANCER , cilt.221, 2025 (SCI-Expanded, Scopus)

21. Efficacy of Second-Line Treatments After Atezolizumab and Bevacizumab in Advanced Hepatocellular Carcinoma and Related Prognostic Factors: A Multicenter Study by the Turkish Oncology Group (TOG)

Majidova N., YASLIKAYA Ş., Mıldanoglu M. M., Coskun A., ERCAN UZUNDAL D., Sahin T. K., et al.

The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology , cilt.36, sa.5, ss.293-301, 2025 (SCI-Expanded, Scopus, TRDizin)

22. Carcinoma erysipeloides, a case-report and review of the sixty-nine cases in the literature

EROĞLU İ., ÜNER A., GÜRLER F., YAZICI O., ÖZET A., ÖZDEMİR N.

American Journal of the Medical Sciences , cilt.369, sa.4, ss.485-490, 2025 (SCI-Expanded, Scopus)

23. The Comparison of FLOT and DCF Regimens as Perioperative Treatment for Gastric Cancer

Uçar G., Sekmek S., Karahan İ., Ergün Y., Aydın İsak Ö., Tunç S., et al.

ONCOLOGY , cilt.103, sa.2, ss.128-133, 2025 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

24. Could Sarcopenia Be Related to Chemotherapy in Gastrointestinal Cancer? A Cross-Sectional Study Including Comprehensive Geriatric Assessment

SILAY K., Uçar G., Eren T., SELVİ ÖZTORUN H., YAZICI O., ÖZDEMİR N.

Journal of Clinical Medicine , cilt.14, sa.3, 2025 (SCI-Expanded, Scopus)

25. Assessment of the CALLY Index, a Novel Immunonutrivite Marker, in Perioperatively Treated Gastric Cancer Patients Perioperatif Tedavi Görmüş Mide Kanseri Hastalarında Yeni Bir İmmünonutrisyonel Belirteç Olarak CALLY İndeksi Değerlendirilmesi

AKDOĞAN O., Yücel K. B., YAZICI O., ÖZET A., ÖZDEMİR N.

Gazi Medical Journal , cilt.36, sa.1, ss.85-90, 2025 (ESCI, Scopus, TRDizin)

26. Prognostic Significance of Maspin Expression in Locally Advanced Rectal Cancer: A Comprehensive Study

Atbiner Eroğlu G., Sütcüoğlu O., ÖĞÜT B., ÖZDEMİR N.

Turk Onkoloji Dergisi , cilt.40, sa.1, ss.20-29, 2025 (ESCI, Scopus, TRDizin)

27. On the species of Rhyacionia Hubner [1825] (Lepidoptera : Tortricidae) in Turkey

Seven S., Ozdemir M., Ozdemir Y., Bozkurt V.

PHYTOPARASITICA , cilt.33, sa.2, ss.123-128, 2005 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

Yayınlar & Eserler

Yayın

Yayın (WoS)

Yayın (Scopus)

Atıf (WoS)

H-İndeks (WoS)

Atıf (Scopus)

H-İndeks (Scopus)

Atıf (Scholar)

H-İndeks (Scholar)

Atıf (TrDizin)

H-İndeks (TrDizin)

Atıf (Diğer Toplam)

Proje

Tez Danışmanlığı

Açık Erişim